Skip to main content
SpringerLink
Log in

Modulation of Arabinosylcytosine Metabolism during Leukemia Therapy

  • Chapter
Purine and Pyrimidine Metabolism in Man VIII

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 370))

Abstract

Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. A nucleoside antimetabolite such as arabinosylcytosine (ara-C) is a pro-drug that must enter cells and be phosphorylated to the ara-C triphosphate (ara-CTP) before it can elicit biologic activity. Thus, knowledge of the pharmacokinetics of the triphosphate in target cells and an understanding of the mechanisms by which this active form of the drug act are indispensable to the rational design of treatment protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kantarjian, HM, Estey, E.H., Plunkett, W., et al, Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia Am J Med 81: 387 (1986).

    Article  PubMed  CAS  Google Scholar 

  2. Estey, E., Plunkett, W., Dixon, D.O., et al, Variables predicting response to high dose cytosine arabinoside therapy with refractory acute leukemia. Leukemia 1: 580 (1987).

    PubMed  CAS  Google Scholar 

  3. Liliemark, J.O., Plunkett, W., Dixon, D.O., Relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 5’-triphosphate levels in leukemia cells during treatment with high-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 45: 5952 (1985).

    PubMed  CAS  Google Scholar 

  4. Plunkett, W., Iacoboni, S., Estey, E., et al, Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12[suppl 3]: 20 (1985).

    PubMed  CAS  Google Scholar 

  5. Plunkett, W., Liliemark, J.O., Estey, E., et al, Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14[suppl 1]: 159 (1987).

    PubMed  CAS  Google Scholar 

  6. Plunkett, W., Liliemark, J.O., Adams, T.M., et al, Saturation of 1-β-D-arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during highdose l-β-D-arabinofuranosylcytosine therapy. Cancer Res 47: 3005 (1987).

    PubMed  CAS  Google Scholar 

  7. Estey, E., Plunkett, W., Kantarjian H., et al, Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): Confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Lenk Lymph 10[suppl]: 115 (1993).

    Article  Google Scholar 

  8. Hiddemann, W., Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Ann Hematol 62: 119 (1991).

    Article  PubMed  CAS  Google Scholar 

  9. Grant, S., Biochemical modulation of cytosine arabinoside. Pharmacol Ther 28: 29 (1990).

    Article  Google Scholar 

  10. Zittoun, R., Zittoun, J., Marquet, J., et al, Modulation of l-β-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia Cancer Res 45: 5186 (1985).

    PubMed  CAS  Google Scholar 

  11. Barlogie, B., Plunkett, W., Raber, M., et al, In vivo cellular kinetic and pharmacological studies of l-β-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia Cancer Res 41: 1227 (1981).

    PubMed  CAS  Google Scholar 

  12. Shackney, S.E., Ford, S.S., Occhipinti, S.J., et al, Schedule optimization of hydroxyurea and l-β-D-arabinofuranosylcytosine in sarcoma 180 in vitro. Cancer Res 42: 4339 (1982).

    PubMed  CAS  Google Scholar 

  13. Cannistra, S.A., Groshek, P., Griffin, J.D., Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3: 328 (1989).

    PubMed  CAS  Google Scholar 

  14. Tanaka, M., Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leukemia Res 17: 585 (1993).

    Article  CAS  Google Scholar 

  15. Bhalla, K., Holladay, C., Arlin, Z., et al, Treatment with interleukin-3 plus granulocytemacrophage colony-stimulating factors improves the selectivity of ara-C in vitro against acute myeloid leukemia blasts. Blood 78: 2674 (1991).

    PubMed  CAS  Google Scholar 

  16. Plunkett, W., Nowak, B., Keating, M.J., Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71: 479(1987).

    PubMed  CAS  Google Scholar 

  17. Plunkett, W., Hug, V., Keating M.J., et al, Quantitation of l-β-D-arabinofuranosylcytosine 5’-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving l-β-D-arabinofuranosylcytosine therapy. Cancer Res 40: 488 (1980).

    Google Scholar 

  18. Shewach, D.S., Plunkett, W., Correlation of cytotoxicity with total intracellular exposure to 9-β-D-arabinofuranosyladenine-5’-triphosphate. Cancer Res 42: 3637 (1982).

    PubMed  CAS  Google Scholar 

  19. Gandhi, V., Plunkett, W., Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48: 329 (1988).

    PubMed  CAS  Google Scholar 

  20. Gandhi, V., Nowak, B., Keating, M.J., et al, Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patient with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74: 2070 (1989).

    PubMed  CAS  Google Scholar 

  21. Gandhi, V., Estey, E., Keating, M.J., et al, Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11: 116 (1993).

    PubMed  CAS  Google Scholar 

  22. Tafuri, A., Andreeff, M., Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4: 826 (1990).

    CAS  Google Scholar 

  23. Bhalla, K, Birkhofer, M., Arlin, Z., et al, Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2: 810 (1988).

    PubMed  CAS  Google Scholar 

  24. Gandhi, V., Du, M., Kantarjian, HM et al, Effect of granulocyte-macrophage colonystimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 8: 1463, 1994.

    PubMed  CAS  Google Scholar 

  25. Koistinen, P., Wang, G, Yang, G.S., et al, OCI/AML-4 an acute myeloblastic leukemia cell line: Regulation and response to cytosine arabinoside. Leukemia 5: 704 (1991).

    PubMed  CAS  Google Scholar 

  26. Koistinen, P., Wang, G, Curtis, J.E., et al, Granulocyte macrophage colony-stimulating factor and interleukin-3 protect leukemic blasts cells from ara-C toxicity. Leukemia 5: 789 (1991).

    PubMed  CAS  Google Scholar 

  27. Gandhi, V., Du, M., Nowak, B., et al, Granulocyte colony-stimulating factor modulates the metabolism of fludarabine in leukemia blasts during therapy. Proc Am Assoc Cancer Res 35: 210 (1994).

    Google Scholar 

  28. Gandhi, V., Kemena, A., Keating, M.J., et al, Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52: 897 (1992).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Investigation, MD. Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Varsha Gandhi & William Plunkett

  2. Department of Hematology, MD. Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Elihu Estey

Authors
  1. Varsha Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elihu Estey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William Plunkett
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Indiana University School of Medicine, Indianapolis, Indiana, USA

    Amrik Sahota

  2. Indiana University, Bloomington, Indiana, USA

    Milton W. Taylor

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gandhi, V., Estey, E., Plunkett, W. (1995). Modulation of Arabinosylcytosine Metabolism during Leukemia Therapy. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2584-4_27

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6105-3

  • Online ISBN: 978-1-4615-2584-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation